Pomotrelvir

DB18975InvestigationalSmall molecule

Pomotrelvir is under investigation in clinical trial NCT05543707 (PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19).

Mechanism: Pharmacologically active on Replicase polyprotein 1ab
Curator reviewed
Formula / weight: C₂₃H₂₆ClN₅O₃ · 455.94 g/mol (avg)
Also known as: 1H-Indole-2-carboxamide, 7-chloro-N-[(1S)-2-[[(1S)-1-cyano-2-[(3S)-2-oxo-3-piperidinyl]ethyl]amino]-1-(cyclopropylmethyl)-2-oxoethyl]- · 7-chloro-N-[(2S)-1-({(1S)-1-cyano-2-[(3S)-2-oxopiperidin-3-yl]ethyl}amino)-3- cyclopropyl-1-oxopropan-2-yl]-1H-indole-2-carboxamide
Code names: PBI-0451

Resolves to

Compound

UNII6XHD59349RCAS2713437-86-4

Structure

InChIKeyBNMFQWUHWYJTRI-BQFCYCMXSA-NSMILESClC1=C2NC(=CC2=CC=C1)C(=O)N[C@@H](CC1CC1)C(=O)N[C@@H](C[C@@H]1CCCNC1=O)C#N

Targets

P0DTD1rep

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pomotrelvir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account